{"product_id":"ogn-bcg-matrix","title":"(OGN) Organon \u0026 Co. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Organon \u0026amp; Co. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the actual analysis, so you can check the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexplanon, 3-year contraceptive implant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNexplanon is Organon \u0026amp; Co.’s 3-year contraceptive implant and a core women’s-health brand in a durable, prescription-led market. Its long-acting reversible format supports repeat demand and steady physician use, which helps explain its Star status in the BCG view. Protecting office access and placement support matters, because even small share gains can defend future cash flow. If growth holds through 2026, Nexplanon can stay one of Organon \u0026amp; Co.’s top cash engines later.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHadlima, adalimumab biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHadlima sits in a large adalimumab biosimilar pool that opened after Humira lost exclusivity, and the switching base is still widening. In 2025, adalimumab biosimilars continued to win payer deals, so share can still rise with the right access and price. For Organon, that makes Hadlima a growth asset, but only if contracting stays strong and volume keeps scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon Biosimilars, 5-product portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon Biosimilars spans five products: Brenzys, Renflexis, Hadlima, Ontruzant, and Aybintio. The set sits in a market where biosimilars have already delivered $36 billion in U.S. savings since 2015, and more originator biologics are still losing exclusivity.\u003c\/p\u003e\n\u003cp\u003eIf Organon keeps winning reimbursement and substitution access, this portfolio can scale fast on low incremental cost. That growth runway is why it fits the Star bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWomen’s Health franchise, contraceptive and fertility care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon \u0026amp; Co.’s women’s health franchise stays a core growth engine because contraceptives and fertility care are repeat-use, prescription-led categories with broad global access needs. In Organon’s latest reporting, the portfolio remains commercially supported because it is still not fully mature, so it looks more like a growth asset than a legacy cash cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat use supports steady demand\u003c\/li\u003e\n\u003cli\u003eFertility care needs ongoing prescriptions\u003c\/li\u003e\n\u003cli\u003eGlobal access expands the runway\u003c\/li\u003e\n\u003cli\u003eCommercial support signals growth stage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReproductive care platform, global prescription reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon's reproductive care platform has global prescription reach through wholesalers, retailers, medical facilities, and managed-care channels, so growth brands can scale fast. In BCG terms, that mix of broad access and demand growth fits \"Star\" economics, with strong share and room to expand. The company uses this base to defend leading positions in women's health and fertility care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad channel mix\u003c\/li\u003e\n\u003cli\u003eFast market scaling\u003c\/li\u003e\n\u003cli\u003eStar-like growth profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon’s Star Assets: Nexplanon and Hadlima Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNexplanon and Hadlima are the clearest Stars in Organon \u0026amp; Co.’s BCG mix. Nexplanon supports repeat use in contraception, while Hadlima rides a biosimilar market that is still expanding after Humira loss of exclusivity. Organon Biosimilars also benefits from $36 billion in U.S. biosimilar savings since 2015.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexplanon\u003c\/td\u003e\n\u003ctd\u003eRepeat-use demand\u003c\/td\u003e\n\u003ctd\u003eLong-acting contraceptive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHadlima\u003c\/td\u003e\n\u003ctd\u003eOngoing share gains\u003c\/td\u003e\n\u003ctd\u003eAdalimumab biosimilar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOrganon \u0026amp; Co. BCG Matrix spots where to invest, hold, or divest across its pharma portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Organon \u0026amp; Co. BCG Matrix that spots cash cows and drag units fast for clearer portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOrganon \u0026amp; Co. Reference Sources provide a clear, traceable evidence trail that boosts credibility and speeds investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor are mature branded lipid products with slow growth but steady installed demand. Their long physician familiarity and lower promotion needs usually support higher margin contribution than new launches, making them a classic BCG cash cow. In a branded statin market that is now mostly off-patent, this legacy franchise can help fund newer growth bets at Organon \u0026amp; Co.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingulair, montelukast respiratory and allergy brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSingulair, Organon \u0026amp; Co.’s montelukast brand, sits in a mature asthma and allergy market where growth is limited but demand stays steady. Because the product is long established and needs little launch spend, it can keep throwing off cash with low reinvestment. That is classic Cash Cow behavior: high reliability, modest growth, and strong free cash flow support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosamax, osteoporosis therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFosamax, launched in 1995, is a mature alendronate brand with a long track record in osteoporosis care. Organon reported $6.4 billion in 2024 net sales, and a stable, low-growth brand like Fosamax can keep adding dependable cash with limited commercial spend if access holds. That kind of branded longevity is exactly why it fits the Cash Cow bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProscar, BPH treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProscar, Organon \u0026amp; Co.'s finasteride for symptomatic benign prostatic hyperplasia, sits in a mature category with steady repeat use and low growth dependence. That profile fits a Cash Cow: sales are driven by an established patient base, not by rapid market expansion.\u003c\/p\u003e\n\u003cp\u003eIts value is recurring cash flow, not breakout growth, which matters in a BCG Matrix because mature therapy areas often keep producing while requiring limited new capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished BPH therapy\u003c\/li\u003e\n\u003cli\u003eRepeat-prescription demand\u003c\/li\u003e\n\u003cli\u003eLow growth, stable cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePropecia, male pattern hair loss brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePropecia is a legacy dermatology and urology brand with a durable prescriber base. Male pattern hair loss affects about 50% of men by age 50, so demand stays steady even though growth is low. That fits a classic Cash Cow profile: recognizable, mature, and cash generative with limited reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, steady demand\u003c\/li\u003e\n\u003cli\u003eStrong brand recall\u003c\/li\u003e\n\u003cli\u003eDurable prescriber base\u003c\/li\u003e\n\u003cli\u003eCash support, low capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon’s Legacy Brands Keep the Cash Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon \u0026amp; Co.’s Cash Cows are its mature legacy brands—Zetia, Singulair, Fosamax, Proscar, and Propecia—which have steady repeat demand, low growth, and limited launch spend, so they keep generating cash for the portfolio. With Organon \u0026amp; Co. reporting $6.4 billion in 2024 net sales, these brands still matter most for dependable free cash flow, not expansion. Their value is stable prescription volume in off-patent markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eCash Cow signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZetia\u003c\/td\u003e\n\u003ctd\u003eMature lipid therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingulair\u003c\/td\u003e\n\u003ctd\u003eSteady allergy demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosamax\u003c\/td\u003e\n\u003ctd\u003eLong-running osteoporosis use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eOrganon \u0026amp; Co. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Organon \u0026amp; Co. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the complete, polished report ready for immediate use. Once purchased, it’s available for download and ready to edit, print, or share. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsmanex, inhaled asthma corticosteroid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAsmanex faces heavy generic pressure in a mature inhaled-corticosteroid market, so Organon \u0026amp; Co. has limited room to grow share. With lower-cost alternatives widely available, pricing power stays weak and long-term returns stay thin. That profile fits a Dog in the BCG Matrix if 2025-2026 sales remain only low and cash generation does not improve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDulera, asthma controller therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDulera sits in a mature inhaled-respiratory market with heavy competition from branded and generic ICS\/LABA options. In the U.S., asthma affects about 25 million people, but growth is limited and share gains are hard to win. If Organon \u0026amp; Co. keeps spending on promotion while Dulera revenue stays modest, the asset fits a Dog in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClarinex, Aerius allergy brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClarinex and Aerius sit in a crowded seasonal-allergy market where generic desloratadine and OTC antihistamines keep prices tight, so growth and margin upside stay limited. That is classic Dog territory: low growth, weak share, and little pricing power. Organon should treat these brands as maintenance assets, not expansion bets, and fund only the cash they still generate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiprosone, Elocon dermatology brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiprosone and Elocon fit the Dog bucket: they operate in a mature, price-led dermatology market where generic betamethasone and mometasone products keep pressure on pricing and share. Organon does not break out 2025 brand sales for these products, which itself suggests limited strategic weight and low incremental growth. In this setting, cash returns are usually weak and reinvestment needs stay low.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeneric competition stays intense\u003c\/li\u003e\n\u003cli\u003eTopical steroid market is mature\u003c\/li\u003e\n\u003cli\u003ePricing power is limited\u003c\/li\u003e\n\u003cli\u003eDog classification is consistent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCelestone, Diprospan injectable corticosteroids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelestone and Diprospan are legacy injectable corticosteroids in Organon \u0026amp; Co.'s mature portfolio. They face generic and therapeutic substitution, so revenue can linger but growth upside is thin. In BCG terms, they fit Dogs: low-growth, low-share assets that merit harvest, not heavy reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOld, mature products\u003c\/li\u003e\n\u003cli\u003eSubstitution pressure stays high\u003c\/li\u003e\n\u003cli\u003eCash yes, growth no\u003c\/li\u003e\n\u003cli\u003eLow priority for capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon’s Legacy Brands Face Generic Pressure and Thin Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon \u0026amp; Co.’s Dogs are mostly legacy brands in mature, price-led markets where generic and OTC pressure keeps growth weak and margins thin. Asmanex, Dulera, Clarinex, Aerius, Diprosone, Elocon, Celestone, and Diprospan fit low-growth, low-share profiles, so they are better for cash harvest than reinvestment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsmanex\u003c\/td\u003e\n\u003ctd\u003eGeneric pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDulera\u003c\/td\u003e\n\u003ctd\u003eWeak share growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClarinex\/Aerius\u003c\/td\u003e\n\u003ctd\u003eOTC and generic squeeze\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrenzys, etanercept biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrenzys sits in a growing etanercept biosimilar pool, but share is still being fought over. Amgen said Enbrel brought in $3.7 billion in 2024, showing the base market is still large and contested. If Organon wins more payer and tender deals, Brenzys can scale, but it still needs share-building, so it fits a Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRenflexis, infliximab biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRenflexis sits in a growing but crowded infliximab biosimilar market, where lower-cost biologic demand keeps expanding. In the U.S., infliximab biosimilars face direct pressure from Pfizer’s Inflectra, Samsung Bioepis\/Merck’s Renflexis peers, and the reference drug Remicade, so pricing stays tight. Organon must keep spending to defend volume, which fits a Question Mark. It has upside, but not clear leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOntruzant, trastuzumab biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOntruzant, Organon’s trastuzumab biosimilar, serves HER2-positive breast and gastric cancer, where biosimilars still have long runway. Its share is still driven by payer contracting and hospital adoption, so volume can move fast when access opens. Until that broader access turns into durable sales, Ontruzant stays a Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAybintio, bevacizumab biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAybintio sits in Organon \u0026amp; Co.s Question Mark bucket because bevacizumab biosimilars are a growing oncology swap market, but wins depend on tender access and hospital uptake. That creates high upside with no clear moat yet. In Organons 2025 base, this is still a share-gain story, not a scale winner.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAybintio has upside.\u003c\/li\u003e\n\u003cli\u003eTender wins drive volume.\u003c\/li\u003e\n\u003cli\u003eInstitutional uptake stays uncertain.\u003c\/li\u003e\n\u003cli\u003eHigh growth, low share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFertility treatments, expansion opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFertility treatments sit in Organon \u0026amp; Co.'s women’s health pipeline as a clear growth option, but the company is not yet a dominant player. To turn clinical demand into wider use, it needs more education, reimbursement support, and channel reach, which keeps this unit in Question Mark territory for end-2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, low share\u003c\/li\u003e\n\u003cli\u003eNeeds sales and education spend\u003c\/li\u003e\n\u003cli\u003eValue rises with broader adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat mix can pay off, but only if Organon converts awareness into repeat prescribing and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon’s Biosimilar Bets: Growth Exists, Moat Doesn’t\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrenzys, Renflexis, Ontruzant, and Aybintio stay in Organon \u0026amp; Co.'s Question Mark bucket: each sells into a growing biosimilar market, but share is still unsettled and access-led. In 2025, Organon still had to spend on tenders, payer wins, and hospital uptake, so upside exists but no clear moat yet.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrenzys\u003c\/td\u003e\n\u003ctd\u003eLarge etanercept pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenflexis\u003c\/td\u003e\n\u003ctd\u003eCrowded infliximab set\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOntruzant\u003c\/td\u003e\n\u003ctd\u003eAccess drives volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAybintio\u003c\/td\u003e\n\u003ctd\u003eTender-led growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234773475593,"sku":"ogn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ogn-bcg-matrix.webp?v=1785727337","url":"https:\/\/dcfanalyst.com\/products\/ogn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}